Listed

BridgeBio Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 4, 2021 and accepted by EDGAR at Nov 4, 2021, 16:21 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$2.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$56.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-07-01 to 2021-09-30$1.5mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-01-01 to 2021-09-30$1.6mus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2021-07-01 to 2021-09-30$104.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$328.8mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-01 to 2021-09-30$46.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$137.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30−$149.5mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$411.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$11.1mus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$31.6mus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30−$161.0mus-gaap:ProfitLoss
Net income9 months2021-01-01 to 2021-09-30−$434.2mus-gaap:ProfitLoss
Operating cash flow9 months2021-01-01 to 2021-09-30−$364.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$10.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2021-01-01 to 2021-09-30$198.5mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-09-30$180.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$639.7mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$781.5mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$95.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$1.52bnus-gaap:Liabilities
Long-term debtAt period end2021-09-30$103.1mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2021-09-30−$743.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-21-003080. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.